ECP Pharma’s Path Forward Clearer After FDA’s Response To Pre-IND Submission On Its Neurological, CNS Diseases Drug Products

MIAMI–(BUSINESS WIRE)–ECP Pharma has received a favorable, positive written response from the FDA regarding its Pre-IND submission of novel drugs for targeted indications with no clinically proven treatment options using underutilized APIs (Active Pharmaceutical Ingredients). The FDA provided a clear order of when clinical studies should be conducted by ECP Pharma, which increases the likelihood … [Read more…]

$200+ Billion Cancer Diagnostics Markets by Test, Technology, Application, End User, & By Region – Global Forecast and Analysis 2022-2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Cancer Diagnostics Market, By Test, Technology, Application, End User, & By Region – Forecast and Analysis 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global cancer diagnostics market was valued at USD 128.30 Billion in 2021, and it is expected to reach a value of USD 203.60 Billion by 2027, at … [Read more…]

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces, that the initiation of a Proof of Concept (POC) clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation … [Read more…]

Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer

SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced top-line results from the KEYNOTE-899 phase 1b/2 clinical trial of GX-I7 (efineptakin alfa) in combination with pembrolizumab. The results indicated that GX-I7 in combination … [Read more…]

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting

BEIJING–(BUSINESS WIRE)–Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Poster Presentation 1: Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer (HNC) harboring FGF/FGFR gene aberrations Abstract Number: 6039 In the dose-escalation … [Read more…]

New MYLUNG Consortium Research Demonstrates Remote Pharmacist Intervention Significantly Increases Clinical Trial Enrollments in Community Oncology Setting

Average monthly enrollment nearly doubled with pharmacy intervention Remote pharmacist easily adapted into clinic workflows in community practices THE WOODLANDS, Texas–(BUSINESS WIRE)–Results from the second phase of the broad, collaborative MYLUNG ConsortiumTM research study in non-small cell lung cancer (NSCLC) were presented by The US Oncology Network (The Network), US Oncology Research and Ontada® at … [Read more…]

Korro Bio to Participate in 2022 Jefferies Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New York, NY, on Thursday, June 9, 2022, at 10:30 a.m. EDT. About Korro … [Read more…]

Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes

NEW ORLEANS–(BUSINESS WIRE)–$TNDM #TNDM–Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2™ insulin pump with Control-IQ® technology. The data was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New … [Read more…]

Horizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in June: Goldman Sachs 43rd Annual Global Health Care Conference Date: Tuesday, June 14, 2022 Presentation Time: 11 a.m. ET The conference presentation will be webcast live and may be accessed by visiting Horizon’s website at http://ir.horizontherapeutics.com. A … [Read more…]

Retractable Technologies, Inc. Announces Reduction in Workforce

LITTLE ELM, Texas–(BUSINESS WIRE)–Retractable Technologies, Inc. (NYSE American: RVP) reports that it has reduced its workforce by approximately 16% as a result of the substantial completion of its facility expansion efforts and the completion of U.S. government orders to provide its products for COVID-19 vaccination efforts. The staff reduction primarily affects its production, operations and … [Read more…]